Gasent Blesa JM, Garde Noguera J, Laforga Canales JB, Giner Bosch V, Alberola A, Soler Tortosa M, Peris Godoy M, Sanchez JL, Provencio Pulla M, Alberola Candel V (2012): Phase II Trial of Concomitant Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine and Intensity-Modulated Radiotherapy (IMRT) in Rectal Cancer. Journal of Gastrointestinal Cancer, 43(4):553–561.
DOI:10.1007/s12029-012-9364-7

Citations received: 1

Gasent Blesa JM, Giner Marco V, Giner-Bosch V, Cerezuela Fuentes P, Alberola Candel V (2011): Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. American Journal of Clinical Oncology, 34(2):155–159.
DOI:10.1097/COC.0b013e3181d6b453

Impact factor (2011): 2.005. JCR ranking: 123/193.
Citations received: 8

San Matías S, Clemente M, Giner-Bosch V (2011): Classification Models for Predicting a Patient Clinical Status: Discussion on the Case of Chemotherapy-induced Neutropenia Duration. Treatment Strategies - Oncology, 2(2):124–127.
http://viewer.zmags.com/publication/20b83b27#/20b83b27/124

San Matías S, Clemente M, Giner-Bosch V, Giner V (2011): Predicting the duration of chemotherapy-induced neutropenia: new scores and validation. Annals of Oncology, 22(1):181–187.
DOI:10.1093/annonc/mdq332

Impact factor (2011): 6.425. JCR ranking: 18/196.
Citations received: 5

Gasent Blesa JM, Alberola Candel V, Giner Marco V, Giner-Bosch V, Provencio Pulla M, Laforga Canales JB (2010): Experience with fulvestrant acetate in castration-resistant prostate cancer patients. Annals of Oncology, 21(5):1131–1132.
DOI:10.1093/annonc/mdq010